Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
SAN CLEMENTE, Calif., June 01, 2017 -- David Steenblock, an osteopathic physician based in San Clemente, CA, is uniquely qualified to address toxicity in the human body through his use of EDTA Chelation Therapy.
Dr. Steenblock uses EDTA (EthyleneDiamineTetraAcetic Acid) Chelation Therapy, a procedure that removes heavy metals from the blood, and consistently improves blood flow and relieves symptoms associated with atherosclerosis in over 80% of patients treated.
“It’s been observed that patients being treated for acute lead intoxification with EDTA with cardiovascular disease, showed improved stress tolerance and less chest pain with physical exertion, “ said Dr. Steenblock.
Dr. Steenblock believes that the benefits of EDTA chelation can improve circulation; reduce cholesterol levels, decrease high blood pressure; and lower insulin requirements in diabetics.
In addition, Dr. Steenblock uses EDTA Chelation Therapy with a combination of hyperbaric oxygen therapy, leading to significant neurologic improvements for stroke patients.
Dr. David Steenblock is a leading-edge physician in many fields of medicine, from stroke care, to acute brain trauma, to generative and cell-based medicine in the treatment of ALS, Cerebral Palsy and other chronic and degenerative diseases. For more information about Dr. Steenblock’s work in stem cell therapies, visit www.stemcellmd.org.
CONTACT: Irene Doti [email protected]
